Biomarkers may be disease specific such as cerebrospinal beta amyloid and phosphorylated tau in AD or may be non-specific, offering evidence for neurodegeneration in the form of decreased cerebral glucose uptake and metabolism, and the abnormal accumulation of iron. The gene discussed is MAPT; the disease is Alzheimer disease.